Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Praxis Precision Medicines Inc (NQ: PRAX ) 60.60 -0.11 (-0.18%) Streaming Delayed Price Updated: 9:43 AM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 47,669 Open 60.71 Bid (Size) 60.05 (2) Ask (Size) 61.08 (4) Prev. Close 60.71 Today's Range 59.91 - 61.49 52wk Range 13.01 - 67.21 Shares Outstanding 44,712,538 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Praxis Precision Medicines to Participate in Upcoming Investor Conferences Today 8:00 EDT From Praxis Precision Medicines, Inc. Via GlobeNewswire Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine September 04, 2024 Via Benzinga Performance YTD +189.95% +189.95% 1 Month +13.23% +13.23% 3 Month +36.95% +36.95% 6 Month +4.20% +4.20% 1 Year +178.62% +178.62% More News Read More Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday September 04, 2024 Via Benzinga Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations September 04, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire What 6 Analyst Ratings Have To Say About Praxis Precision Medicine August 05, 2024 Via Benzinga Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews June 18, 2024 Via Benzinga Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug September 03, 2024 Via Benzinga Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine September 03, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 September 02, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results August 14, 2024 Via Benzinga PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024 August 13, 2024 Via InvestorPlace Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 13, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 August 05, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Are We Having Fun Yet? Stocks Sell Off On Massive Volume August 03, 2024 Via Talk Markets Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails July 24, 2024 Via Investor's Business Daily Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Quarterly & Long-Term Portfolios For The Win July 06, 2024 Via Talk Markets Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst June 24, 2024 Via Benzinga Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure June 20, 2024 Via Investor's Business Daily 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session May 31, 2024 Via Benzinga Praxis Precision Medicines to Participate in Upcoming Investor Conferences May 17, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know May 16, 2024 Via Benzinga PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024 May 13, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
